BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181231
DTEND;VALUE=DATE:20190202
DTSTAMP:20260730T002212
CREATED:20181231T024641Z
LAST-MODIFIED:20181231T025644Z
UID:20971-1546214400-1549065599@ces.b2sg.org
SUMMARY:Clinical Scientist
DESCRIPTION:This position reports to the Head of Translational Medicine and will work in a collaborative\, cross-functional project team environment. The successful candidate will bring proven leadership skills and a strong background in clinical research in cancer therapeutics. This person will be involved in the translational clinical activities across a growing\, early-stage portfolio of small molecule therapeutics\, including the implementation of strategic development plans and actively participating in the conduct of clinical studies for multiple development-stage programs at FORMA Therapeutics Inc.  \nResponsibilities \n\nImplement clinical development strategies/plans for novel drug candidates in oncology and non- oncology indications as part of a cross-functional project team.\nWork closely with the Head of Translational Medicine\, project teams and the Translational Biology group to incorporate the therapeutic directions and patient selection strategies into clinical protocols\nSupport the medical monitor for clinical protocols\nPartner with Clinical Operations on clinical trial conduct and monitoring\, including GCP\, patient eligibility\, safety monitoring\, AE and SAE tracking and reporting and protocol deviations\nSupport timely and high quality cleaning\, analysis\, interpretation and communication of data in ongoing and completed studies\nReview regulatory documentation and other communications\, including IND\, IB\, annual reports\, CSR\, abstracts\, manuscripts and presentations\nCoordinate relationships with external key opinion leaders and investigators and lead/participate in investigator meetings\, advisory boards and site visits.\nWork and partner with internal and external (CRO\, investigator) stakeholders\nAdhere to and implement quality standards and SOPs in clinical development\n\nPosition Requirements: \n\nThe successful candidate’s position and title will be commensurate with experience\nBachelor’s degree with at least 5 years’ industry experience in oncology drug development\nExperience with small molecule therapeutics preferred\nExperience in Phase I protocol development and clinical strategy development is required\nKnowledge of the regulatory environment and experience with working with regulatory authorities is required\nStrong understanding of cancer biology and ability to integrate biological knowledge into clinical development strategy\nAdditional experience in non-oncology therapeutic areas (Immunology) is a plus\nA creative problem solver with the proven ability to work independently and collaboratively in a fast-paced\, results-oriented and dynamic environment\nExcellent interpersonal skills and a demonstrated ability to work well within team structure is essential\nStrong written and verbal communication skills.\nAbility to travel up to 20%
URL:https://ces.b2sg.org/event/forma-30dec18/
LOCATION:FORMA Therapeutics\, Watertown\, MA\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/12/forma1.jpg
END:VEVENT
END:VCALENDAR